Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 9:45 PM
Ignite Modification Date:
2025-12-24 @ 9:45 PM
NCT ID:
NCT06116032
Eligibility Criteria:
Inclusion Criteria:
* Cancer patients receiving or will receive immunotherapy under FDA- approved indication (e.g. checkpoint inhibitor therapy with pembrolizumab, nivolumab, or ipilimumab, or cellular immunotherapy).
* Participants are eligible regardless of the type of prior therapy (i.e. prior immunotherapy treated participants can be included).
Exclusion Criteria:
* Pregnant women/fetuses/neonates
* Prisoners
* Decision-impaired individuals
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT06116032
Study Brief:
Protocol Section:
NCT06116032